GNPX
Genprex Inc
NASDAQ: GNPX · HEALTHCARE · BIOTECHNOLOGY
$0.98
+12.07% today
Updated 2026-04-30
Market cap
$8.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-17.40
Dividend yield
—
52W range
$1 – $55
Volume
1.1M
Genprex Inc (GNPX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-103.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-171.5%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-4.1%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.9%
2026-03-27
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-27 | $-1.15 | — | $1.88 | $1.77 | -5.9% |
| 2025-11-14 | $-5.00 | -669.2% | $4.14 | $4.04 | -2.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | — | $-1.15 | — | — | — |
| 2025-09-30 | $-0.65 | $-5.00 | -669.2% | — | — |
| 2025-06-30 | $-0.74 | $-8.47 | -1044.6% | — | — |
| 2025-03-31 | $-2.54 | $-0.26 | +89.8% | $9916.00 | -57.2% |
| 2024-12-31 | $-0.39 | $-0.42 | -8.8% | — | — |
| 2024-09-30 | $-1.93 | $-1.23 | +36.3% | — | — |
| 2024-06-30 | $-2.30 | $-3.00 | -30.4% | — | — |
| 2024-03-31 | $-2.54 | $-3.69 | -45.3% | $23154.00 | — |
| 2023-12-31 | $-3.93 | $-3.96 | -0.8% | — | — |
| 2023-09-30 | $-0.11 | $-0.13 | -18.2% | — | — |
| 2023-06-30 | $-0.12 | $-0.15 | -25.0% | — | — |
| 2023-03-31 | $-0.12 | $-0.19 | -58.3% | — | — |
Frequently asked questions
Has Genprex Inc beaten earnings estimates?
Genprex Inc has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -103.4% over the last 3 quarters.
How does GNPX stock react to earnings?
GNPX stock has moved an average of -4.1% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.